 |
|
Interferon Therapy of Multiple Sclerosis
edited by Anthony T. Reder, 550 pp, $195, New York, NY, Marcel Dekker Inc, 1997.
Arch Neurol. 1998;55:747-748.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
It is difficult for publications to keep up with a rapidly advancing field, particularly when it is in book form with 46 authors describing their particular part of the elephant, but it is important to try. We cannot wait until the basic science is solid and the clinical trials have answered all the questions. This book makes an admirable effort with surprisingly timely work.
It is fashionable to comment on the unevenness of multiauthored works, but that is actually not a major issue here. The editor has done his job of seeking outstanding people to cover all aspects of the issue. One presumes we will later see comparable work on other new therapies for multiple sclerosis (MS) and then a second phase when these new therapies are combined.
Interferon beta-1b (Betaseron) was the first of 3 new drugs approved by the US Food and Drug Administration for MS, followed by . . . [Full Text of this Article]
|
